Latest results FY2026 · Prices updated Oct 30, 2026
HQ: Chuo-ku, TokyoFounded 20058,009 employeesWebsite
A leading Japanese pharmaceutical company. It is a global leader in oncology with its proprietary Antibody Drug Conjugate (ADC) technology, focusing on innovative medicine discovery.
Business segments (share of revenue)
Latest results
FY2026
vs. same period a year earlier
Company forecastFY2027
| Segment | Share | Revenue | Operating profit | Margin |
|---|---|---|---|---|
| Oncology Business Unit | 48% | ¥608.8B | ¥0 | 0.0% |
| Japan Pharmaceutical Business | 38% | ¥485.8B | ¥0 | 0.0% |
| American Regent Business | 14% | ¥182.2B | ¥0 | 0.0% |
Close (Oct 30, 2026)
¥2,754-28.7% (1Y)
Daiichi Sankyo -28.7% over 1Y, 43.6pt below the industry average (23 companies, +14.8%).
Reference chart of daily closing prices, not real-time quotes (split-adjusted; weekly closes before the last year). Updated Oct 30, 2026.
| Period | Revenue | Op. profit | Net income | Total assets | Revenue YoY |
|---|---|---|---|---|---|
| 2026FY | ¥2.1T | ¥229.1B | ¥259.9B | ¥4.0T | +12.6% |
| 2025FY | ¥1.9T | ¥331.9B | ¥295.8B | ¥3.5T | +17.8% |
| 2024FY | ¥1.6T | ¥211.6B | ¥200.7B | ¥3.5T | +25.3% |
| 2023FY | ¥1.3T | ¥120.6B | ¥109.2B | ¥2.5T | +22.4% |
| 2022FY | ¥1.0T | ¥73.0B | ¥67.0B | ¥2.2T | +8.6% |
| 2021FY | ¥962.5B | ¥63.8B | ¥76.0B | ¥2.1T | — |
Sources: annual securities reports, earnings releases and other public disclosures (Jan 2026)
Data may contain input errors. For reference only; we accept no responsibility for its accuracy.
